Chugai Pharmaceutical has scrapped the in-house development of five drug candidates among 14 projects in PI-II, President and CEO Osamu Okuda said at the company’s earnings briefing on July 24. The decision reflects a reprioritization of the pipeline based on…
To read the full story
Related Article
BUSINESS
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Shionogi’s Delgocitinib Wins Nod in China through LEO Pharma
November 18, 2026
- RaQualia’s Reflux Therapy Scores Approval in Brazil
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





